PVI, PeerView Institute for Medical Education

Happy #Thanksgiving, everyone! 🦃🍁 On this special day, we gather with loved ones and reflect on what we are thankful for. We want to express our heartfelt gratitude to each and every one of you—our wonderful faculty and learners and dedicated staff at PVI. Your support and hard work make all the difference in our journey. What are your Thanksgiving traditions? 🥧 We would love to hear from you! #BeThankful #ThanksgivingDinner #FamilyTime #Friendsgiving

Hypertrophic cardiomyopathy (#HCM) is estimated to affect as many as 1 in 200 people, with a mortality rate about 3 times greater than that of those without HCM. Historically, when patients progressed to severe symptomatic obstructive HCM (oHCM), their options were limited to invasive treatments or medications that inconsistently addressed symptoms. In 2022, a first-in-class cardiac myosin inhibitor (CMI) was approved for oHCM. CMIs target the underlying pathophysiology of HCM, alleviate symptoms, improve functional outcomes, and are potentially disease-modifying (a characteristic relevant beyond oHCM). What's most important for cardiologists to know about the latest data? This Clinical Consult event with Milind Desai, MD, MBA, FACC, FAHA, FESC, and Anjali Tiku Owens, MD, explores the clinical research and real-world evidence for CMIs through the lens of everyday patient care. During the event, Drs. Desai and Owens will be answering your questions in real-time in a live chat. Join PeerView Live and The Mended Hearts, Inc. virtually on December 12 or January 9 at 7:00 PM EST! https://bit.ly/2024HCML #MedEd #Cardiology #HFSA2024 This activity is supported by an educational grant from Bristol Myers Squibb.

#NSCLC updates from #MaTOS led by Dr. Liu - bit.ly/LakeTahoe24Y

Transthyretin cardiac amyloidosis (ATTR-CA, #ATTRCA, #CardiacAmyloidosis) leads to cardiomyopathy due to the extracellular accumulation of misfolded transthyretin protein. Alarmingly, new epidemiologic studies suggest that specific genetic variants that cause the disease are far more common than previously suspected. Recent developments have led to the emergence of targeted therapies that alter the inevitable course of ATTR-CA, transforming it from a progressive, potentially fatal disease into a treatable one. By the end of this MasterClass & Practicum event with Michelle Kittleson, MD, PhD, and Senthil Selvaraj, MD, MS, MA, cardiologists will be better prepared to support patients through the diagnostic and treatment process to give them the best chance possible at long-term, favorable outcomes. From identification of the signs and symptoms of ATTR-CA to early intervention using evidence-based guidelines through creating individualized treatment plans using the latest evidence, this live virtual event has it all! Plus, during the event, Drs. Kittleson and Selvaraj will be answering your questions in real-time in a live chat. Join PeerView Live virtually December 3 or January 7 at 7 PM EST! https://bit.ly/24ATTR-CAL #MedEd #Cardiology #HFSA2024 This activity is supported by an educational grant from BridgeBio Pharma, Inc.

What an incredible turnout tonight at #SNO2024! A packed room of engaged attendees eager to learn about the latest advancements in #IDH-mutant #glioma care. Thank you to everyone who joined us and made this event a tremendous success! 🎉 A heartfelt thank you to Drs. Manmeet Ahluwalia, MD, MBA, FASCO, and Patrick Wen for leading such an exceptional symposium. Your expertise in targeted therapies and biomarker testing is invaluable in advancing patient care and improving outcomes. Special thanks to the American Brain Tumor Association (ABTA) for collaborating with us on this impactful program.

#Glioma updates from #SNO led by Drs. Ahluwalia - bit.ly/2024GliomaL

💜 Today is #WorldPancreaticCancerDay, a day to stand together in raising awareness and supporting those affected by this challenging disease. Pancreatic cancer is often detected late, making early awareness and research critical. Join PVI, PeerView Institute for Medical Education, in honoring patients, survivors, and their families while also recognizing the healthcare professionals and researchers tirelessly working toward better treatments and outcomes. Together, we can shine a light on the fight against #pancreaticcancer and make a difference. #WorldPancreaticCancerDay #PancreaticCancerAwareness #WPCD

Innovation in prostate cancer treatment has brought advances to patients throughout the disease continuum, from localized disease and high-risk biochemical recurrence through mHSPC and mCRPC. Additionally, novel treatments such as hormonal therapies, PARP inhibitors, and radioligands used in monotherapy and combination regimens are setting new standards of care and improving patient outcomes. Register now to join PeerView Live, in partnership with ZERO Prostate Cancer, during the 2024 Society for Urologic Oncology Annual Meeting for a Clinical Consults session focused on patient-centric approaches for prostate cancer care. Through discussion of real-world cases, the expert faculty panel led by Neal Shore, MD, FACS, will link evidence supporting the efficacy and safety of a variety of treatment regimens with strategies for incorporating modern therapeutic approaches into individualized prostate cancer care across the disease spectrum. Topics will include identification of biochemical recurrence, implementation of genetic testing, team-based management of adverse events, and patient education strategies to optimize treatment adherence. Join the experts in person at #SUO24 or online on Friday, December 6, at 12:00 PM CST/1:00 PM EST to get a roadmap for navigating patient-centric prostate cancer care; https://bit.ly/24ProstateL #MedEd #UroOnc #Urology #Oncology This activity is supported by independent educational grants from Astellas Pharma and Pfizer Inc., Bayer HealthCare Pharmaceuticals Inc., The Janssen Pharmaceutical Companies of Johnson & Johnson, and Novartis Pharmaceuticals Corporation.

Join Us for a Prostate Cancer Clinical Consult at #SUO24! Led by Dr. Neal Shore and featuring Drs. Gordon A. Brown & Tanya Barauskas Dorff, this session will provide expert insights on developing patient-centered treatment plans using the latest clinical and real-world evidence. 📅 Friday, December 6, 12:00 PM CST 📍 In-person at #SUO24 or online at 12:15 PM CST / 1:15 PM EST In partnership with ZERO Prostate Cancer. Don’t miss it—register now!

Explore the Latest on Cardiac Myosin Inhibition! Join Milind Desai MD MBA and Anjali Owens for an expert discussion on CMIs, featuring real-world insights and practical guidance. Engage with the experts as they answer your questions in real-time during a live chat. Don’t miss this opportunity—join PeerView Live and The Mended Hearts, Inc. virtually on December 12 or January 9 at 7:00 PM EST!